BASEL, Switzerland, Jan. 22 /Xinhua-PRNewswire/ -- New Phase III data presented at the American Society of Clinical Oncology Gastrointestinal Symposium (ASCO GI) continue to demonstrate the excellent efficacy of two of Roche’s innovative cancer drugs Xeloda and Avastin, which offer improved survival for patients with advanced colorectal cancer. The NO16966 study showed that:
-- XELOX (oral Xeloda plus oxaliplatin) is at least as effective as
FOLFOX-4 in terms of overall survival
-- The addition of Avastin to either XELOX or FOLFOX leads to a
statistically significant improvement in progression-free survival, as
determined by an independent review committee (IRC)
"Overall, these results confirm the role of XELOX as the most convenient and patient-friendly treatment option in this disease area, which is very encouraging for colorectal cancer patients and healthcare providers," said Professor Jim Cassidy, co-lead investigator for study NO16966 and Cancer Research UK Professor of Oncology and Chair of Medical Oncology, Beatson Oncology Centre, at the University of Glasgow, Scotland. "In addition, the independent review confirms that by adding Avastin to any oxaliplatin-based regimen we can improve progression-free survival times even further, which we knew all along based on the second-line data with FOLFOX plus Avastin."
In the treatment of advanced (metastatic) colorectal cancer, these data showed that XELOX reached its primary endpoint:
-- The chemotherapy combination XELOX is as effective in terms of time
patients live without their disease progressing (PFS) as FOLFOX-4.
-- Overall survival data of the first 634 patients enrolled prior to the
introduction of Avastin indicate that XELOX is at least comparable to
FOLFOX-4.
These data add to the results of previous studies, further endorsing that Xeloda should replace infused 5-FU/leucovorin in colorectal cancer regimens.
The IRC which conducted a blinded analysis of the scans confirmed that Avastin reached its primary endpoint:
-- The benefit provided by Avastin when added to chemotherapy
(FOLFOX or XELOX) significantly improved progression-free
survival by 43% compared to chemotherapy alone, as assessed
by the IRC. A previous analysis presented in October 2006 showed
an advantage of 20%.
-- Specifically there was also a statistically significant
improvement in PFS when assessing the addition of Avastin to
either the XELOX or FOLFOX subgroup (p<0.007)
No new safety findings related to Avastin or Xeloda were observed in the trial.
Further analyses are ongoing and updated results will be presented at future scientific meetings. Based on findings from this study and the NO16967 and E3200 studies, Roche will be approaching worldwide regulatory authorities for new file submissions with Xeloda and Avastin respectively in advanced colorectal cancer.
In 2004, colorectal cancer was one of the leading cancers and accounted for 13 percent of all cancers in Europe.(1) A World Health Organization report suggested that in 2005, 655,000 people worldwide died from colorectal cancer.(2)
Notes to Editors:
About the Study
NO16966
NO16966 is a large, international Phase III trial which finally recruited 2,034 patients. It was originally planned to compare XELOX vs FOLFOX as first-line treatment in metastatic colorectal cancer:
-- XELOX (Xeloda plus oxaliplatin) vs FOLFOX-4 (intravenous bolus and
infusional 5-fluorouracil plus oxaliplatin)
The two-arm study recruited 634 patients.
After release of the pivotal Avastin data in colorectal cancer in 2003, the protocol was amended to investigate using a 2 by 2 factorial design:
-- XELOX + placebo vs XELOX + Avastin (7.5 mg/kg q3w) vs. FOLFOX
+ placebo vs FOLFOX + Avastin (5.0 mg/kg q2w).
The primary objective was to answer two questions: 1) whether the XELOX regimen is non-inferior to FOLFOX; 2) whether the addition of Avastin to chemotherapy improved results compared to chemotherapy alone. The secondary endpoints included overall survival, overall response rates, time to, and duration of, response and safety profile.
Results presented previously at the European Society of Medical Oncology (ESMO) meeting in October 2006 of the entire study population (N=2,034) show that:
-- XELOX is as effective as FOLFOX in terms of PFS (hazard
ratio: 1.05; upper limit of the 97.5 percent confidence interval
was below the non-inferiority margin of 1.23).
-- Adding Avastin to chemotherapy (FOLFOX and XELOX) significantly
improved PFS compared to chemotherapy alone (hazard ratio: 0.83).
This means that adding Avastin to either chemotherapy combination
improves the chances of delaying progression of the disease by 20
percent.
-- No unexpected safety findings were identified for either XELOX or
Avastin:
-- Adverse events which occurred at a rate greater than 10 percent
in any of the treatment arms were: diarrhoea (FOLFOX, 11.2 percent of
patients; XELOX, 20.2 percent of patients), neutropenia (FOLFOX, 43.8
percent of patients, XELOX, 7.0 percent of patients) and neurosensory
toxicity (FOLFOX, 16.5 percent of patients; XELOX, 17.4 percent of
patients).
-- The percentage of gastrointestinal perforations was 0.6 percent in the
Avastin arms compared to 0.3 percent in the placebo group. Grade 3/4
arterial thromboembolic events occurred in 1.7 percent vs 1.0 percent
respectively. Grade 3/4 proteinuria was reported for 0.6 percent of
all patients receiving Avastin. Wound healing complications were not
observed in a higher frequency than in the placebo group (0.1 vs 0.3
percent).
About Xeloda (capecitabine)
Xeloda is licensed in more than 90 countries worldwide including the EU, USA, Japan, Australia and Canada and has been shown to be an effective, safe, simple and convenient oral chemotherapy in treating over 1 million patients to date.
Roche received marketing authorisation for Xeloda as a first-line monotherapy (by itself) in the treatment of metastatic colorectal cancer (colorectal cancer that has spread to other parts of the body) in most countries (including the EU and USA) in 2001. Xeloda has also been approved by the European Medicines Agency (EMEA) and U.S. Food and Drug Administration (FDA) for adjuvant (post-surgery) treatment of colon cancer in March and June 2005, respectively.
Xeloda is licensed in combination with Taxotere (docetaxel) in women with metastatic breast cancer (breast cancer that has spread to other parts of the body) and whose disease has progressed following intravenous (i.v.) chemotherapy with anthracyclines. Xeloda monotherapy is also indicated for treatment of patients with metastatic breast cancer that is resistant to other chemotherapy drugs such as paclitaxel and anthracyclines. Xeloda recently received approval in South Korea for the first-line treatment of patients with locally advanced (metastatic) pancreatic cancer, in combination with gemcitabine. Xeloda is licensed in South Korea for the first-line treatment of stomach cancer.
The most commonly reported adverse events with Xeloda include diarrhoea, abdominal pain, nausea, stomatitis and hand-foot syndrome (palmar-plantar erythrodysesthaesia).
About Avastin (bevacizumab)
Avastin is the first treatment that inhibits angiogenesis -- the growth of a network of blood vessels that supply nutrients and oxygen to cancerous tissues. Avastin targets a naturally occurring protein called Vascular Endothelial Growth Factor (VEGF), a key mediator of angiogenesis, thus choking off the blood supply that is essential for the growth of the tumour and its spread throughout the body (metastasis).
In Europe, Avastin was approved in early 2005 and in the US in February 2004 for first-line treatment of patients with advanced colorectal cancer. It received another approval in the US in June 2006 as a second-line treatment for patients with advanced colorectal cancer. The first filing for Avastin in Japan occurred in April 2006 for the treatment of advanced colorectal cancer. Most recently following priority review, the world’s first angiogenesis inhibitor was approved by the FDA in October for the treatment of non-small cell lung cancer (NSCLC); a filing for the same indication was submitted to EU authorities in August.
Roche and Genentech are pursuing a comprehensive clinical programme investigating the use of Avastin in various tumour types (including colorectal, breast, lung, pancreatic cancer, ovarian cancer, renal cell carcinoma and others) and different settings (advanced and adjuvant iepost-operation). The total development programme is expected to include over 40,000 patients worldwide.
For more information, please visit http://www.avastin-info.com
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology.
Roche employs roughly 70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet ( http://www.roche.com ).
All trademarks used or mentioned in this release are legally protected.
Further Information Available from Media Relations Contacts:
-- Colorectal cancer fact sheet
-- Xeloda in colorectal cancer fact sheet
-- Avastin in colorectal cancer fact sheet
-- Xeloda fact sheet
-- Avastin fact sheet
-- Roche in oncology:
http://www.roche.com/pages/downloads/company/pdf/mboncology05e_a.pdf
-- Roche: http://www.roche.com
-- Broadcast quality B-roll including doctor, caregiver and patient
interviews is available for download via http://www.thenewsmarket.com
References:
1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Annals of Oncology 2005;16:481-488
2. World Health Organization, http://www.who.int/healthinfo/statistics/bodprojections2030/en/index.html
